NICE gives thumbs-up to Amgen bone drug

The U.K.'s cost-effectiveness watchdog has approved Amgen's (AMGN) osteoporosis drug Prolia (denosumab) for routine use by the National Health Service in postmenopausal patients who are at increased risk of osteoporotic bone fractures. Report

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.